Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Other financing activities (2024)

Arrowhead Pharmaceuticals' Other financing activities history spans 5 years, with the latest figure at $5.0 million for Q4 2024.

For Q4 2024, Other financing activities changed N/A year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, up 59.54%, while the annual FY2025 figure was $5.0 million, 59.54% up from the prior year.
Other financing activities reached $5.0 million in Q4 2024 per ARWR's latest filing, up from $3.1 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $5.0 million in Q4 2024 to a low of $3.1 million in Q3 2024.